Sorafenib treatment for recurrent stage T1 bilateral renal cell carcinoma in patients with Von Hippel- Lindau disease: A case report and literature review.
暂无分享,去创建一个
[1] V. Zagonel,et al. First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel–Lindau (VHL) disease: clinical outcome and patterns of radiological response , 2015, Familial Cancer.
[2] R. Kurzrock,et al. Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art , 2014, Cancer and Metastasis Reviews.
[3] A. Vortmeyer,et al. Renal cancer in von Hippel–Lindau disease and related syndromes , 2013, Nature Reviews Nephrology.
[4] G. Fuller,et al. Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] W. Linehan,et al. Oncological outcomes of partial nephrectomy for multifocal renal cell carcinoma greater than 4 cm. , 2010, The Journal of urology.
[6] K. Ahrar,et al. Patterns of intervention for renal lesions in von Hippel‐Lindau disease , 2008, BJU international.
[7] S. Richard,et al. Local recurrence after nephron-sparing surgery in von Hippel-Lindau disease. , 2007, Urology.
[8] R. Nelson,et al. Complications after percutaneous radiofrequency ablation of renal tumors. , 2005, Urology.
[9] J. Gnarra,et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. , 1993, Science.
[10] A. Novick,et al. Renal transplantation in patients with renal cell carcinoma and von Hippel-Lindau disease. , 1994, Urology.